AIM
EGRX

Acrospire Investment Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Acrospire Investment Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-200
Closed -$16K – 1523
2017
Q2 		$16K Sell
200
-200
-50% -$16.4K 0.02% 1647
2017
Q1 		$33K Sell
400
-1,100
-73% -$81.8K 0.03% 1303
2016
Q4 		$119K Buy
+1,500
New +$109K 0.05% 792
2016
Q3 		– Sell
-700
Closed -$27K – 2198
2016
Q2 		$27K Sell
700
-300
-30% -$12.5K 0.02% 1429
2016
Q1 		$41K Buy
+1,000
New +$63.4K 0.03% 1117

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Acrospire Investment Management's EGRX Position: Q3 2017 in Review

Acrospire Investment Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2017, closing a stake of 200 shares — an estimated $16K sold.

Acrospire Investment Management first reported a position in EGRX in Q1 2016 and held it in 5 quarters. The position peaked at $119K in Q4 2016. 169 funds tracked by Wall St. Rank hold EGRX as of Q3 2017.

  • Acrospire Investment Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 200 Eagle Pharmaceuticals, Inc. shares in Q3 2017, an estimated $16K.
  • Acrospire Investment Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2016 and held it in 5 quarters.
  • Acrospire Investment Management's Eagle Pharmaceuticals, Inc. position peaked at $119K in Q4 2016.
  • 169 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.